MedTrace Logo

A Lassa Fever Vaccine Trial in Adults and Children Residing in West Africa

NCT05868733 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 612

Last updated 2025-05-11

No results posted yet for this study

Summary

A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of rVSV∆G-LASV-GPC Vaccine in Adults and Children Residing in West Africa

Conditions

  • Lassa Fever

Interventions

DRUG

Day 1 Lower Dose (2×106 pfu)

rVSV∆G-LASV-GPC

DRUG

Day 1 Higher Dose (1×107 pfu)

rVSV∆G-LASV-GPC

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Coalition for Epidemic Preparedness Innovations

    collaborator OTHER

  • International AIDS Vaccine Initiative

    lead NETWORK

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Months
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-03-06
Primary Completion
2026-12-31
Completion
2027-04-30
FDA Drug
Yes

Countries

  • Ghana
  • Liberia
  • Nigeria

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05868733 on ClinicalTrials.gov